The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs - Pharmaceutical Research
- ️Benet, Leslie Z.
- ️Tue Jun 30 2009
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 1976;455:152–162.
Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 2000;38(2):69–74.
Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 2003;306(2):778–786.
Mizuno N, Sugiyama Y. Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab. Pharmacokinet. 2002;17(2):93–108.
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005;22(1):11–23.
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995;12(3):413–420.
Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008;38(7–8):889–935.
Zaïr ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics. 2008;9(5):597–624.
Ciarimboli G. Organic cation transporters. Xenobiotica. 2008;38(7–8):936–971.
Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008;38(7-8):778–801.
Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica. 2008;38(7–8):833–862.
Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 2008;15(20):1981–2039.
Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch. 2007;453(5):735–744.
Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006;25(4):231–259.
Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 2007;47:566–578.
Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 2008;14(46):7068–7074.
Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin. Pharmacol. Ther. 2007;81(2):265–269.
Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic, and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 2008;23(4):223–235.
Nakamura T, Yamamori M, Sakaeda T. Pharmacogenetics of intestinal absorption. Curr. Drug Deliv. 2008;5(3):153–69.
Food and Drug Administration. http://www.fda.gov/cder/drug/drugInteractions/tableSubstrates.htm#top (accessed 12/11/2008), part of U.S. Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/Cder/ (accessed 12/11/2008).
van Montfoort JE, Müller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J. Pharmacol. Exp. Ther. 2001;298(1):110–115.
Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol. Cancer Ther. 2008;7(9):3081–3091.
Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol. 2000;58(2):335–340.
Satlin LM, Amin V, Wolkoff AW. Organic anion transporting polypeptide mediates organic anion/HCO3− exchange. J. Biol. Chem. 1997;272(42):26340–26345.
Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am. J. Physiol. Gastrointest. Liver Physiol. 2007;293(1):G271–278.
Kosters A, Karpen SJ. Bile acid transporters in health and disease. Xenobiotica. 2008;38(7–8):1043–1071.
Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. www.fda.gov/cder/guidance/index.htm (accessed 12/17/2008), part of U.S. Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/Cder/ (accessed 12/11/2008).
Takagi T, Ramachandran C, Mermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain and Japan. Mol. Pharmaceut. 2006;3:631–643.
Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Houssain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmaceut. 2004;1:85–96.
Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol. Pharmaceut. 2007;4(4):608–614.
Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 2008;25(3):483–488.
Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10–11):1015–1051.
Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter MRP2/Mrp2 in liver tissues and isolated hepatocytes from rat, dog, monkey and human. Drug Metab. Dispos. 2009;37(1):66–73.
Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 2006;95(12):2673–2683.
Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 2006;23(8):1675–1686.
Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 2008;35(5):383–396.
Arthur JM. The MDCK cell line is made up of populations of cells with diverse resistive and transport properties. Tissue Cell. 2000;32(5):446–450.
Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 2002;19(10):1400–1416.
Chen ML, Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol. Pharmaceutics. 2009;6(1):74–81.
C.L. Larregieu and L.Z. Benet. The confounding FDA redefinition of intestinal permeability in terms of extent of absorption. AAPS 2009 Annual Meeting Abstract.
Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, et al. Concentration-dependent effect of naringin on intestinal absorption of b1-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res. 2009;26(3):560–567.
Fagerholm U. The role of permeability in drug ADME/PK, interactions and toxicity-presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm. Res. 2008;25(3):625–638.
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 1995;58(5):492–497.
Cao X, Yu LX, Barbaciru C, Landowski CP, Shin HC, Gibbs S, et al. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharmaceut. 2005;2(4):329–340.
Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002;300(3):1036–1045.
Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 2003;305(1):306–314.
Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 2007;81(5):669–678.
Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 2000;68(4):345–355.
Lee JS, Obach RS, Fisher MB. Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development. New York: Marcel Dekker; 2003.
Sesink AL, Arts IC, de Boer VC, Breedveld P, Schellens JH, Hollman PC, et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 2005;67(6):1999–2006.
Su Y, Hu P, Lee SH, Sinko PJ. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J. Pharm. Sci. 2007;10(4):519–536.
Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 2007;81(3):362–370.
Y. Kato, T. Miyazaki, T. Kano, T. Sugiura, Y. Kubo, and A. Tsuji. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci. 2009;98(7):2529–2539.
Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, et al. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci. 2006;78(24):2852–2859.
Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS Class III drugs. Mol. Pharmaceut. 2009;6(1):19–28.
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999;104(2):147–53. Erratum in: J. Clin. Invest. 110(4):571 (2002).
Food and Drug Administration. Guidance for Industry: Food- Effect Bioavailability and Fed Bioequivalence Studies. http://www.fda.gov/cder/guidance/index.htm (accessed 12/17/2008).
Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 2008;60(6):717–733.
Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2003;304(1):223–228.
Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol. Pharmaceut. 2004;1(1):49–56.
Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 2009;328(2):652–662.
Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 2007;81(2):194–204.
Zheng HX, Huang Y, Frassetto L, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther. 2009;85(1):78–85.
Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics. 2008;18(5):424–433.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 2008;83(2):273–280.
Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos. 2008;36(5):911–915.
Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. U S A. 2005;102(20):7274–7279.
Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy. 2003;23(8):979–987.
Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Rel. 1999;62(1–2):25–31.
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gasotroenterology. 2001;120:525–533.
Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br. J. Clin. Pharmacol. 2007;64(3):353–362.
Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John’s wort. J. Psychopharmacol. 2004;18(2):262–276.
Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J. Pharm. Sci. 2006;95(9):1984–1993.
Tannergren C, Knutson T, Knutson L, Lennernäs H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 2003;55(2):182–190.
Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm. Res. 2008;25(12):2869–2877.
Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab. Dispos. 2008;36(6):1088–1096.
Luna- Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55(8):1364–1375.
Kis E, Nagy T, Jani M, Molnár E, Jánossy J, Ujhelly O, et al. Leflunomide and its metabolite A771726, are high affinity substrates of BCRP: implications for drug resistance. Ann. Rheum. Dis. 2009;68(7):1201–1207.
Engel K, Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol. Pharmacol. 2005;68(5):1397–1407.
Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab. Dispos. 2007;35(10):1956–1962.
Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics. 2008;18(5):439–448.
Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandström R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin. Pharmacol. Ther. 2008;84(1):52–62.
Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab. Dispos. 2008;36(4):796–805.
Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, et al. Application and limitation of inhibitors in drug-transporter interactions studies. Int. J. Pharmaceut. 2008;356(1–2):12–18.
Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 2007;81(4):495–502.
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164–172.
Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res. 2008;25(10):2320–2326.
Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007;67(14):6965–6972.
Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci. 2008;97(2):712–725.
Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 2007;35(8):1333–1340.
Lohitnavy M, Lu Y, Lohitnavy O, Chubb LS, Hirono S, Yang RS. A possible role of multidrug resistance-associated protein 2 (Mrp2) in hepatic excretion of PCB126, an environmental contaminant: PBPK/PD modeling. Toxicol. Sci. 2008;104(1):27–39.
Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica. 2007;37(10–11):1295–1310.
De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 2007;35(10):1766–1780.
Wang Z, Yan A, Yuan Q, Gasteiger J. Explorations into modeling human oral bioavailability. Eur. J. Med. Chem. 2008;43(11):2442–2452.
Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharmaceut. 2008;5(5):760–775.
Bonen A, Heynen M, Hatta H. Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl. Physiol. Nutr. Metab. 2006;31(1):31–39.
Food and Drug Administration. Drug Information: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers http://www.fda.gov/Cder/drug/drugInteractions/tableSubstrates.htm#(accessed 12/17/2008), part of U.S. Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/Cder/ (accessed 12/11/2008).
Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 2006;80(6):607–620.
Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 2005;280(10):9610–9617.
Bijvelds MJ, Jorna H, Verkade HJ, Bot AG, Hofmann F, Agellon LB, et al. Activation of CFTR by ASBT-mediated bile salt absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 2005;289(5):G870–879.
Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol. 2004;65:512–519.
Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M, et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet. Genomics. 2005;15(2):83–90.
Bodo A, Barkos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 2003;278(26):23529–23537.
Tian Q, Zhang J, Chan SY, Tan TM, Duan W, Huang M, et al. Topotecan: topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab. 2006;7(1):105–118.
Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftoxime and cefazolin in the kidney. Mol. Pharmacol. 2007;71(6):1591–1597.
Huber RD, Gao B, Pfandler M-AS, Zhang-Fu W, Leuthold S, Hagenbuch B, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am. J. Physiol. Cell Physiol. 2007;292:C795–C806.
Gao B, Huber RD, Wenzel A, Vavricka SR, Ismair MG, Reme C, et al. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exper. Eye Res. 2005;80(1):61–72.
Jedlitschky G, Burchell B, Keppler D. cGMP: the multidrug resistance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 2000;275(39):30069–30074.
Farias M, San Martin R, Puebla C, Pearson JD, Casado JF, Pastor-Anglada M, et al. Nitric oxide reduces adenosin transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J. Cell Physiol. 2006;208(2):451–460.
Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol. Membr. Biol. 2001;18(2):161–167.
Kirat D, Masuoka J, Hayashi H, Iwano H, Yokota H, Taniyama H, et al. Monocarboxylate transporter (MCT1) plays a direct role in short-chain fatty acids absorption in caprine rumen. J. Physiol. 2006;576(Pt. 2):635–647.
Meredith D, Boyd CAR, Bronk JR, Bailey PD, Morgan KM, Collier ID, et al. PEPT-1: 4-aminomethylbenzoic acid is a non-translocated competitive inhibitor of the epithelial peptide transporter PepT1. J. Physiol. 1998;512(3):629–634.
Knutter I, Theis S, Hartrodt B, Born I, Brandsch M, Daniel H, et al. A novel inhibitor of the mammalian peptide transporter PEPT1. Biochemistry. 2001;40:4454–4458.
Groneberg DA, Eynott PR, Doring F, Dinh QT, Oates T, Barnes PJ, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax. 2002;57(1):55–60.
Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2, and hOCT3. Br. J. Pharmacol. 2002;136:829–836.
Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, et al. Glucuronidation converting methyl 1-(3, 4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6, 7, 8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 2007;322(2):610–618.
Li H, Chen F, Shang Q, Pan L, Shneider BL, Chiang JYL, et al. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. Am. J. Physiol. Gastrointest. Liver Physiol. 2005;288:G60–G66.
Gorraitz E, Sanmartin C, Errasti-Murugarren E, Casado FJ, Pastor-Anglada M, Lostao MP. Interaction of nucleoside-derivatives with the human Na+/nucleoside cotransporters CNT1 and CNT3. FASEB J. 2008;22: lb133.
Li JY, Boado RJ, Pardridge WM. Differential kinetics of transport of 2’, 3’-dideoxyinosine and adenosine via concentrative Na + nucledoside transporter CNT2 cloned from rat blood-brain barrier. J. Pharmacol. Exp. Ther. 2001;299(2):735–740.
Yabuuchi H, Tamai I, Nezu JI, Sakamoto K, Oku A, Shimane M, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 1999;289(2):768–773.
Elimrani I, Lahjouji K, Seidman E, Roy M-J, Mitchell GA, Qureshi I. Expression and localization of organic cation/carnitine transporter OCTN2 in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2003;284:G863–871.
Aye ILMH, Paxton JW, Evseenko DA, Keelan JA. Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes. Placenta. 2007;28(8–9):868–877.
Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002;1:417–425.
Janneh O, Hartkoorn RC, Jones E, Owen A, Ward SA, Davey R, et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br. J. Pharmacol. 2008;155(6):875–883.
Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001;142(5):2005–2012.
Potschka H, Baltes S, Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilep. Res. 2004;58(3):85–91.
Pollex E, Lubetsky A, Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta. 2008;29(8):743–747.
Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley R, Matherly L, Schuetz J. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3): article 14.
Boraldi F, Quuaglino D, Croce MA, Garcia Fernandez MI, Tiozzo R, Gheduzzi D, et al. Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003;22(6):491–500.
Lin W, Buolamwini JK. Synthesis and flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J. Med. Chem. 2007;50:3906–3920.
Robillard KR, Bone DBJ, Hammond JR. Hypoxanthine uptake and release by equilibrative nucleoside transporter 2 (ENT2) of rat microvascular endothelial cells. Microvasc. Res. 2008;75(3):351–357.
Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 2000;275(31):23530–23539.
Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 2005;314(2):876–882.
Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, Fardel O. Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab. Dispos. 2005;33(10):1418–1422.
Leslie EM, Watkins PB, Kim RB, Brouwer KLR. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SCL10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 2007;321(3):1170–1178.
Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J. Pharmacol. Exp. Ther. 1999;291(3):1204–1209.
Khamdung S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, et al. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J. Pharmacol. Sci. 2004;94(2):197–202.
Halwachs S, Kneuer C, Honscha W. Endogenous expression of liver-specific drug transporters for organic anions in rat hepatocytoma fusion cell line HPCT-1E3. Eur. J. Cell Biol. 2005;84(7):677–686.
Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001;276:14581–14587.
Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 2005;67:1954–1965.
Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002;277:2908–2915.
Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 2001;29:1467–1472.
Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 2004;279:22250–22257.
Szatmari I, Vámosi G, Brazda P, Balint BL, Benko S, Széles L, et al. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem. 2006;281:23812–23823.
Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001;276:28857–28865.
Eloranta JJ, Jung D, Kullak-Ublick GA. The human Na + -taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-depende. Mol. Endocrinol. 2006;20:65–79.
Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 2006;66:535–542.
Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002;62:638–646.
Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, et al. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology. 2002;122:1954–1966.
Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res. 2003;20:552–556.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 2000;97(7):3473–3478.
Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 2002;72(2):209–219.
Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 2004;76:418–427.
de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 2007;81:42–49.
Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 2004;76:38–44.
Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 2005;4:650–658.
Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, et al. Role of BCRP 421C > A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 2006;373:99–103.
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003;73:554–564.
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 2004;75:415–421.
Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 2005;59:602–604.
Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 2005;77:468–478.
Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 2007;82:541–547.
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 2007;82:726–733.
Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol. 2006;62:567–572.
Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Ther. 2006;79:186–196.
Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics. 2006;16:683–691.
Oswald S, Scheuch E, Cascorbi I, Siegmund W. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J. Chromatogr. B. 2006;830:143–150.
Vormfelde SV, Toliat MR, Schirmer M, Meineke I, Nürnberg P, Brockmöller J. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin. Pharamacol. Ther. 2008;83:815–817.
Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 2007;63:1161–1169.
Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11:250–261.